Characteristics and prognostic factor in patients with advanced renal cell carcinoma (RCC) achieving complete response by treatment using biological response modifiers (BRM)

K. Marumo, Y. Huang, M. Oya, M. Tachibana, M. Murai, H. Tazaki

Research output: Contribution to journalArticle


One of 24 patients treated with human lymphoblastoid interferon (IFN), 2 of 20 patients treated by sequential administration of IFN and OK-432, and 3 of 18 patients treated with interleukin 2 achieved a complete response. All 6 patients had been nephrectomized, and had a common type of renal cell carcinoma. Metastatic sites were lung and mediastinum in one patient and lung alone in the other 5 patients. Five of 6 patients developed a recurrence between 11 months and 6 years of disease-free periods and did not respond to primarily effective therapy. The results demonstrated that careful observation is needed even after disappearance of a tumor by treatment with BRMs and establishment of a new modality for recurrent RCD was encouraged.

Original languageEnglish
Pages (from-to)554-556
Number of pages3
Issue number3
Publication statusPublished - 1996 Jan 1



  • Complete response
  • Interferon
  • Interleukin 2
  • OK-432
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this